Calcium channel blockers (CCBs) are first-line agents for hypertension management
1,2 and rank among the 10 most commonly used prescription medications in North America.
3,4 Clinicians may preferentially prescribe CCBs, particularly in older adults, because of their favorable adverse event profile and the limited need for routine laboratory monitoring.
5 However, CCBs commonly cause peripheral edema, with an incidence ranging from 2% to 25% depending on the CCB type, dosage, and duration of therapy.
5-7 Amlodipine poses the greatest concern because it is the most widely used CCB and is more likely to lead to peripheral edema than nondihydropyridine (DHP) CCBs and newer lipophilic DHP CCBs.
5 Peripheral edema can be distressing to patients and can alter their quality of life, prompting individuals to seek medical attention or discontinue therapy.
5